ArticleFolia microbiologica2025
Isolation, identification, and bioactivity evaluation of endophytic fungi from Ruta graveolens: insights into antimicrobial and antioxidant potential.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study presents a comprehensive investigation of endophytic fungi isolated from Ruta graveolens (Rutaceae), evaluating the bioactivity of their extracts in terms of antimicrobial and antioxidant properties, along with preliminary mycochemical profiles. Twenty-seven isolates were identified using morphological and molecular identification (ITS-rDNA sequencing). Phylogenetic analysis classified them into Alternaria (66.7%, dominant in stems), Chaetomium (25.9%, prevalent in leaves), Achaetomium (3.7%), and Stagonosporopsis (3.7%) genera, demonstrating strong tissue specificity. Antibacterial screening (disk diffusion) of the fungal extracts revealed that 52% (14/27) were active; extracts of S4, S9, S20-2, and L11 showed inhibition against Staphylococcus aureus (inhibition zones, 14.5-15.8 mm at 100 mg/mL), while L5, L10, and L11 extracts exhibited dual activity against both S. aureus and Escherichia coli. Antifungal assays of the extracts identified strains S22, L5, and L12 as effective against phytopathogens Alternaria alternata, Pyricularia grisea, and Curvularia lunata (inhibition rates, 54.2-67.5% at 1 mg/mL). Meanwhile, antioxidant evaluation of the extracts highlighted strain L11 for remarkable DPPH and ABTS radical scavenging (IC
Indexed as
Identifiers
41051653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.